PROTEOMIC BIOMARKERS IN SERUM OF THE THYROID CANCER PATIENTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该项目的长期目标是利用血清识别和探索一组针对甲状腺癌类型的蛋白质组生物标记物。这项研究的直接目标是建立标准的方案和程序，用于从血清中重复性分析蛋白质，不仅可以用于甲状腺癌，也可以用于其他癌症和疾病的生物标记物的发现。因此，我们的具体目标是开发SELDI分析前血清分离的标准方案和程序，并优化SELDI-TOF分析条件。这些研究产生的蛋白质组图谱将用于开发计算模型，并为未来的实验设计提供基础。 蛋白质组学研究的进展为侵袭性更小的癌症检测方法和新的癌症生物标志物筛选技术提供了更多的可能性。表面增强激光解吸/电离飞行时间质谱仪(SELDI-TOF)和蛋白质芯片技术(美国BioRad)为蛋白质和多肽的复杂混合物提供了一种快速而灵敏的分析方法。最近，SELDI-TOF已成功地用于确定卵巢、前列腺癌、结直肠癌、乳腺癌、肺癌、胰腺癌、肝癌和脑癌的潜在生物标志物。 我们计划从诊断为甲状腺结节的患者身上收集80份血清样本，并将其转诊为细针抽吸程序，但最初只会使用20份样本来建立方案。 通过静脉穿刺法采集样本，按照标准化方案将血液抽取到血清和血浆采集管中。血清和血浆被等分并立即储存在-80C。血清和血浆样本将分批处理，以避免处理过程中的差异。 到目前为止，我们只收集了8名患者的样本。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The long term purpose of the project is to identify and explore a set of proteomic biomarkers specific to the type of thyroid cancer using blood serum. The immediate objective of this study is to establish standard protocols and procedures for the reproducible analysis of proteins from blood serum that could be used in biomarkers discovery not only in the thyroid cancer, but also other cancers and diseases. Therefore, the specific aim is to develop standard protocols and procedures for serum fractionation prior to SELDI analysis and to optimize SELDI-TOF analysis conditions. The proteomic profiles generated from these studies will be used for the development of computational models and provide the foundation for future experimental designs. Advances in the proteomics study opened more possibilities for less invasive cancer detection methods and for novel cancer biomarkers screening techniques. Surface-Enhanced Laser Desorption/Ionization  Time of Flight mass spectrometry (SELDI-TOF) and ProteinChip technology (BioRad, USA) offer a fast and sensitive method of analysis of a complex mixture of proteins and peptides. Recently SELDI-TOF has been successfully used to identify potential biomarkers for the diagnosis of ovarian, prostate, colorectal, breast, lung, pancreatic, liver, and brain cancers. We plan to collect 80 blood serum samples from patients diagnosed with thyroid nodule and referred for Fine Needle Aspiration procedure, however only a subset of 20 will be used initially to establish protocols. Samples are collected by venipuncture, and the blood is drawn according to the standardized protocols into serum and plasma collection tubes. Serum and plasma are aliquoted and stored immediately in -80C. Serum and plasma samples will be processed in batches to avoid variations in the processing. Up to this day we have collected samples from 8 patients only.